Tag Archives: PTK-0796

Timely New Information on Next-Generation Tetracyclines – Part 2: Eravacycline and Protein Binding

Posted on by — 2 Comments ↓

A recent paper by Thabit describes a curious finding [1]. The authors measured total and free (i.e., nonprotein-bound) eravacycline levels at ascending doses in a mouse model. They found strikingly small increases in free drug levels when titrating up total doses. The effect was rather dramatic: an increase in protein binding from 12% Continue reading Timely New Information on Next-Generation Tetracyclines – Part 2: Eravacycline and Protein Binding→

Timely New Information on Next-Generation Tetracyclines – Part 1: Omadacycline and Cardiac AEs

Posted on by — No Comments ↓

Several interesting articles appeared recently which shed light on the efficacy of eravacycline and the safety of omadacycline, both in Phase 3 and both in a head-to-head race to the market.  Well, the term ‘race’ is bit of a stretch as both drugs have seen very significant delays in development. Omadacycline from Continue reading Timely New Information on Next-Generation Tetracyclines – Part 1: Omadacycline and Cardiac AEs→

ALLPHASE PHARMA – THE FIRST 100 BLOG POSTS

Posted on by — No Comments ↓

After the first 100 blogs, it is appropriate to reflect on reader preferences.  When I arbitrarily select a topic, it is not always clear whether what interests me also interests you. Since its start 1½ years ago, this blog has grown steadily in readership.  So we did a few things right Continue reading ALLPHASE PHARMA – THE FIRST 100 BLOG POSTS→